| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
|
J Clin Oncol
|
2013
|
3.77
|
|
2
|
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
|
Blood
|
2013
|
2.65
|
|
3
|
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2010
|
2.45
|
|
4
|
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
|
J Nucl Med
|
2003
|
1.95
|
|
5
|
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
|
Leuk Lymphoma
|
2011
|
1.57
|
|
6
|
Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
|
J Clin Oncol
|
2009
|
1.47
|
|
7
|
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
|
J Nucl Med
|
2002
|
1.42
|
|
8
|
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
|
J Nucl Med
|
2010
|
1.38
|
|
9
|
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
|
J Clin Oncol
|
2005
|
1.35
|
|
10
|
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
|
Blood
|
2005
|
1.33
|
|
11
|
The radioisotope contributes significantly to the activity of radioimmunotherapy.
|
Clin Cancer Res
|
2004
|
1.22
|
|
12
|
Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
|
Cancer Biother Radiopharm
|
2009
|
1.18
|
|
13
|
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
|
Blood
|
2014
|
1.16
|
|
14
|
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
|
J Clin Oncol
|
2009
|
1.11
|
|
15
|
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
|
Blood
|
2011
|
1.11
|
|
16
|
Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.
|
Cancer
|
2002
|
1.01
|
|
17
|
Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions.
|
Eur J Haematol
|
2002
|
0.95
|
|
18
|
Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.
|
Cancer Biother Radiopharm
|
2012
|
0.92
|
|
19
|
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
|
Cancer
|
2013
|
0.90
|
|
20
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
J Natl Compr Canc Netw
|
2016
|
0.89
|
|
21
|
Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients.
|
J Nucl Med
|
2003
|
0.87
|
|
22
|
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
|
Br J Haematol
|
2014
|
0.86
|
|
23
|
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.86
|
|
24
|
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
|
J Clin Oncol
|
2010
|
0.83
|
|
25
|
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.82
|
|
26
|
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
|
Br J Haematol
|
2013
|
0.81
|
|
27
|
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.79
|
|
28
|
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.
|
Cancer
|
2014
|
0.78
|
|
29
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2008
|
0.78
|
|
30
|
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.78
|
|
31
|
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
32
|
Survival in patients with limited-stage peripheral T-cell lymphomas.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
33
|
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
|
Br J Haematol
|
2014
|
0.76
|
|
34
|
Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.
|
Cancer Biother Radiopharm
|
2013
|
0.75
|
|
35
|
Hodgkin disease/lymphoma.
|
J Natl Compr Canc Netw
|
2008
|
0.75
|
|
36
|
Radioantibodies: where do they fit in?
|
Clin Lymphoma
|
2003
|
0.75
|